Copyright Reports & Markets. All rights reserved.

Global Antiangiogenic Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Antiangiogenic Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Macromolecular Single-target Angiogenesis Inhibitor
    • 1.3.3 Small Molecule Multi-target Angiogenesis Inhibitor
    • 1.3.4 Endogenous Pan-target Angiogenesis Inhibitor
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Antiangiogenic Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Cancer Therapy
    • 1.4.3 Ophthalmic Diseases
    • 1.4.4 Inflammatory and Autoimmune Diseases
    • 1.4.5 Other
  • 1.5 Global Antiangiogenic Drugs Market Size & Forecast
    • 1.5.1 Global Antiangiogenic Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Antiangiogenic Drugs Sales Quantity (2021-2032)
    • 1.5.3 Global Antiangiogenic Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Bayer
    • 2.1.1 Bayer Details
    • 2.1.2 Bayer Major Business
    • 2.1.3 Bayer Antiangiogenic Drugs Product and Services
    • 2.1.4 Bayer Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bayer Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Antiangiogenic Drugs Product and Services
    • 2.2.4 Sanofi Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 Eli Lilly
    • 2.3.1 Eli Lilly Details
    • 2.3.2 Eli Lilly Major Business
    • 2.3.3 Eli Lilly Antiangiogenic Drugs Product and Services
    • 2.3.4 Eli Lilly Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Eli Lilly Recent Developments/Updates
  • 2.4 Roche
    • 2.4.1 Roche Details
    • 2.4.2 Roche Major Business
    • 2.4.3 Roche Antiangiogenic Drugs Product and Services
    • 2.4.4 Roche Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Roche Recent Developments/Updates
  • 2.5 Pfizer
    • 2.5.1 Pfizer Details
    • 2.5.2 Pfizer Major Business
    • 2.5.3 Pfizer Antiangiogenic Drugs Product and Services
    • 2.5.4 Pfizer Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Pfizer Recent Developments/Updates
  • 2.6 Jiangsu Hengrui Pharmaceuticals
    • 2.6.1 Jiangsu Hengrui Pharmaceuticals Details
    • 2.6.2 Jiangsu Hengrui Pharmaceuticals Major Business
    • 2.6.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product and Services
    • 2.6.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
  • 2.7 Chia Tai Tianqing
    • 2.7.1 Chia Tai Tianqing Details
    • 2.7.2 Chia Tai Tianqing Major Business
    • 2.7.3 Chia Tai Tianqing Antiangiogenic Drugs Product and Services
    • 2.7.4 Chia Tai Tianqing Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Chia Tai Tianqing Recent Developments/Updates
  • 2.8 Novartis
    • 2.8.1 Novartis Details
    • 2.8.2 Novartis Major Business
    • 2.8.3 Novartis Antiangiogenic Drugs Product and Services
    • 2.8.4 Novartis Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Novartis Recent Developments/Updates
  • 2.9 AstraZeneca
    • 2.9.1 AstraZeneca Details
    • 2.9.2 AstraZeneca Major Business
    • 2.9.3 AstraZeneca Antiangiogenic Drugs Product and Services
    • 2.9.4 AstraZeneca Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 AstraZeneca Recent Developments/Updates
  • 2.10 Exelixis
    • 2.10.1 Exelixis Details
    • 2.10.2 Exelixis Major Business
    • 2.10.3 Exelixis Antiangiogenic Drugs Product and Services
    • 2.10.4 Exelixis Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Exelixis Recent Developments/Updates
  • 2.11 Boehringer Ingelheim
    • 2.11.1 Boehringer Ingelheim Details
    • 2.11.2 Boehringer Ingelheim Major Business
    • 2.11.3 Boehringer Ingelheim Antiangiogenic Drugs Product and Services
    • 2.11.4 Boehringer Ingelheim Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.12 Eisai
    • 2.12.1 Eisai Details
    • 2.12.2 Eisai Major Business
    • 2.12.3 Eisai Antiangiogenic Drugs Product and Services
    • 2.12.4 Eisai Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Eisai Recent Developments/Updates
  • 2.13 Janssen Biotech
    • 2.13.1 Janssen Biotech Details
    • 2.13.2 Janssen Biotech Major Business
    • 2.13.3 Janssen Biotech Antiangiogenic Drugs Product and Services
    • 2.13.4 Janssen Biotech Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Janssen Biotech Recent Developments/Updates
  • 2.14 Simcere
    • 2.14.1 Simcere Details
    • 2.14.2 Simcere Major Business
    • 2.14.3 Simcere Antiangiogenic Drugs Product and Services
    • 2.14.4 Simcere Antiangiogenic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Simcere Recent Developments/Updates

3 Competitive Environment: Antiangiogenic Drugs by Manufacturer

  • 3.1 Global Antiangiogenic Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Antiangiogenic Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global Antiangiogenic Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Antiangiogenic Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Antiangiogenic Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Antiangiogenic Drugs Manufacturer Market Share in 2025
  • 3.5 Antiangiogenic Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Antiangiogenic Drugs Market: Region Footprint
    • 3.5.2 Antiangiogenic Drugs Market: Company Product Type Footprint
    • 3.5.3 Antiangiogenic Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Antiangiogenic Drugs Market Size by Region
    • 4.1.1 Global Antiangiogenic Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Antiangiogenic Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global Antiangiogenic Drugs Average Price by Region (2021-2032)
  • 4.2 North America Antiangiogenic Drugs Consumption Value (2021-2032)
  • 4.3 Europe Antiangiogenic Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Antiangiogenic Drugs Consumption Value (2021-2032)
  • 4.5 South America Antiangiogenic Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Antiangiogenic Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Antiangiogenic Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global Antiangiogenic Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global Antiangiogenic Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Antiangiogenic Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global Antiangiogenic Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global Antiangiogenic Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Antiangiogenic Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America Antiangiogenic Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America Antiangiogenic Drugs Market Size by Country
    • 7.3.1 North America Antiangiogenic Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Antiangiogenic Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Antiangiogenic Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe Antiangiogenic Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe Antiangiogenic Drugs Market Size by Country
    • 8.3.1 Europe Antiangiogenic Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Antiangiogenic Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Antiangiogenic Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Antiangiogenic Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Antiangiogenic Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Antiangiogenic Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Antiangiogenic Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Antiangiogenic Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America Antiangiogenic Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America Antiangiogenic Drugs Market Size by Country
    • 10.3.1 South America Antiangiogenic Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Antiangiogenic Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Antiangiogenic Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Antiangiogenic Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Antiangiogenic Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Antiangiogenic Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Antiangiogenic Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Antiangiogenic Drugs Market Drivers
  • 12.2 Antiangiogenic Drugs Market Restraints
  • 12.3 Antiangiogenic Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Antiangiogenic Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Antiangiogenic Drugs
  • 13.3 Antiangiogenic Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Antiangiogenic Drugs Typical Distributors
  • 14.3 Antiangiogenic Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Antiangiogenic Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Anti-angiogenic drugs are medications designed to inhibit angiogenesis,which is the process of forming new blood vessels.Anti-angiogenic drugs work by targeting specific molecular pathways involved in angiogenesis.By inhibiting these pathways,they prevent the formation of new blood vessels around tumors,thereby depriving them of the nutrients and oxygen they need to grow.These drugs can be used alone or in combination with other cancer therapies such as chemotherapy or radiation therapy.
    This report is a detailed and comprehensive analysis for global Antiangiogenic Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Antiangiogenic Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antiangiogenic Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antiangiogenic Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Antiangiogenic Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Antiangiogenic Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Antiangiogenic Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Sanofi, Eli Lilly, Roche, Pfizer, Jiangsu Hengrui Pharmaceuticals, Chia Tai Tianqing, Novartis, AstraZeneca, Exelixis, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Antiangiogenic Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Macromolecular Single-target Angiogenesis Inhibitor
    Small Molecule Multi-target Angiogenesis Inhibitor
    Endogenous Pan-target Angiogenesis Inhibitor
    Market segment by Application
    Cancer Therapy
    Ophthalmic Diseases
    Inflammatory and Autoimmune Diseases
    Other
    Major players covered
    Bayer
    Sanofi
    Eli Lilly
    Roche
    Pfizer
    Jiangsu Hengrui Pharmaceuticals
    Chia Tai Tianqing
    Novartis
    AstraZeneca
    Exelixis
    Boehringer Ingelheim
    Eisai
    Janssen Biotech
    Simcere
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Antiangiogenic Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Antiangiogenic Drugs, with price, sales quantity, revenue, and global market share of Antiangiogenic Drugs from 2021 to 2026.
    Chapter 3, the Antiangiogenic Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Antiangiogenic Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Antiangiogenic Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Antiangiogenic Drugs.
    Chapter 14 and 15, to describe Antiangiogenic Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now